Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

GLP-1 weight-loss drugs are cutting calories… and grocery bills, according to a new study from Cornell and Numerator.

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Health Care Health Care   The Big Story MAHA leaders heading for clash over GLP-1 drugs Two of President-elect Trump’s top ...

But a new proposal announced by the Biden administration in November ... But it also comes with a price tag in the tens of ...

This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

In a surprising turn, obesity rates in the United States have ... the South might be linked to the increased use of weight-loss medications, such as semaglutide, known commercially as Ozempic.

Should RFK Jr. be confirmed as HHS secretary, he will wield power over policy details that could shape the trajectory of U.S.